Ftse Mib
32.908,05
0,74%
DAX
18.068,21
0,26%
S&P 500
5.473,23
0,77%
NASDAQ
17.857,02
0,95%
Bitcoin
65.605,56
-1,32%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Kezar Life Sciences Inc (KZR) Kezar Life Sciences Inc (KZR) Notizie

KZR

Kezar Life Sciences (KZR)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KZR
DataOraFonteTitoloSimboloCompagnia
07/06/202423:59Business WireKezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:KZRKezar Life Sciences Inc
04/06/202422:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KZRKezar Life Sciences Inc
29/05/202422:01Business WireKezar Life Sciences to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:KZRKezar Life Sciences Inc
09/05/202422:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KZRKezar Life Sciences Inc
09/05/202422:01Business WireKezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:KZRKezar Life Sciences Inc
06/05/202422:05Business WireKezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:KZRKezar Life Sciences Inc
14/03/202421:01Business WireKezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business UpdateNASDAQ:KZRKezar Life Sciences Inc
28/02/202422:01Business WireKezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care ConferenceNASDAQ:KZRKezar Life Sciences Inc
27/02/202400:30Business WireEverest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus NephritisNASDAQ:KZRKezar Life Sciences Inc
14/02/202412:50Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:KZRKezar Life Sciences Inc
17/01/202423:09Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KZRKezar Life Sciences Inc
09/01/202422:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KZRKezar Life Sciences Inc
21/11/202322:01Business WireKezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:KZRKezar Life Sciences Inc
13/11/202322:01Business WireKezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:KZRKezar Life Sciences Inc
03/10/202322:10Business WireKezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive OfficerNASDAQ:KZRKezar Life Sciences Inc
21/09/202302:30Dow Jones NewsStocks to Watch: FedEx, Kezar Life Sciences, TranscatNASDAQ:KZRKezar Life Sciences Inc
21/09/202300:30Business WireKezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast AsiaNASDAQ:KZRKezar Life Sciences Inc
31/08/202322:01Business WireKezar Life Sciences to Participate in Three Upcoming Investor ConferencesNASDAQ:KZRKezar Life Sciences Inc
10/08/202322:01Business WireKezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:KZRKezar Life Sciences Inc
21/06/202322:03Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:KZRKezar Life Sciences Inc
16/06/202322:38Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KZRKezar Life Sciences Inc
16/06/202322:08Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KZRKezar Life Sciences Inc
31/05/202313:00Business WireKezar Life Sciences to Participate in the Jefferies Healthcare ConferenceNASDAQ:KZRKezar Life Sciences Inc
11/05/202322:35Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:KZRKezar Life Sciences Inc
11/05/202322:17Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:KZRKezar Life Sciences Inc
11/05/202322:01Business WireKezar Life Sciences Reports First Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:KZRKezar Life Sciences Inc
27/04/202322:14Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:KZRKezar Life Sciences Inc
27/04/202322:10Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:KZRKezar Life Sciences Inc
17/04/202322:12Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:KZRKezar Life Sciences Inc
14/03/202321:04Edgar (US Regulatory)Post-effective Amendment to an Automatic Shelf Registration of Form S-3asr or Form F-3asr (posasr)NASDAQ:KZRKezar Life Sciences Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KZR

La tua Cronologia

NASDAQ
ITI
Iteris
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network